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BACKGROUND Although the ABSORB bioresorbable vascular scaf-
fold (BVS) is increasingly being used in daily clinical practice for
the treatment of coronary artery disease the exact vascular heal-
ing pattern and the resorption process in humans remains un-
known, since histological data are sparse and derived from animal
studies.
METHODS Between August 2013 and January 2015, the pathology
department of the Academic Medical Center had obtained four au-
topsy cases treated with ﬁve scaffolds, with duration of implantation
ranging from 8 days until 501 days. All available clinical records were
reviewed for patient history, duration of implantation and cause of
death. All autopsies and histological assessments were performed by
dedicated cardiovascular pathologists.
RESULTS One week after BVS implantation scaffold struts were
covered with a ﬁne layer of ﬁbrin and platelets. Smooth Muscle Actin
staining demonstrated at 113 days full coverage of the BVS struts with
smooth muscle cells. Hyaline eosinophilic material inﬁltrating the
scaffold struts, interpreted as resorption of the scaffold material, was
observed at 501 days after implantation. At 8, 113 and 501 days after
implantation we observed the presence of multinuclear foreign body
giant cells adjacent to the struts.CONCLUSIONS Resorption and healing process after BVS implanta-
tion in human patients mirrors observations made in porcine coronary
artery models. The presence of multinucleated foreign body giant
cells both at short term and long term follow up may be related to an
inﬂammatory reaction to the bioresorbable polymer.
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BACKGROUND The MIRAGE bioresorbable vascular scaffold is a novel
technology incorporating a microﬁber (PLA based) helix coil design
mounted on 3 backbones and a biodegradable PLA abluminal coating,
which releases sirolimus as antiproliferative agent (Manli Cardiology
Ltd., Singapore). It has high ﬂexibility and radial strength with strut
thickness ranging from 125 to 150mm (3.0 mm: 125mm; >3.0 mm:
150mm). Additional features of the MIRAGE microﬁber sirolimus-
eluting scaffold (MMSES) include: no time limitation for staying in
artery before deployment, re-entering artery allowed, and no waiting
time for balloon inﬂation during deployment. Our objective was to
report the serial angiographic results at baseline/index procedure and
6-month follow-up.
METHODS The MIRAGE trial was a prospective, randomized, dual
center (Indonesia and Malaysia), ﬁrst-in-human evaluation of the
MMSES for the treatment of diseased coronary vessels. A total of 60
patients with single or up to 2 de novo coronary target lesions
located in native vessels were randomized in a 1:1 ratio for percu-
taneous coronary intervention with the MMSES versus the BVS
(Abbott Vascular, Santa Clara, USA). All patients were assigned for
6-month angiographic re-evaluation, and all angiographic analyses
were performed at an independent angiographic core laboratory
(Cardiovascular Research Center, Sao Paulo, Brazil). The study’s
primary efﬁcacy endpoint was in-scaffold late lumen loss, as
determined by quantitative coronary angiography (QCA) at 6
months.
RESULTS A total of 60 patients (31 patients in group A, 34 lesions; 29
patients in group B, 33 lesions) were randomized from October/2013
to August/2014. There were no signiﬁcant differences in baseline
clinical and angiographic characteristics comparing MMSES and BVS
groups. Considering the overall patient population, LAD was the
most prevalent target coronary vessel (59%) and type C lesions (ac-
cording to the ACC/AHA lesion classiﬁcation) were found in one
third of cases. During procedure, pre dilatation was performed in all
but one case, study scaffold was successfully attempted and
implanted in all cases (100%), and post dilation with an additional
shorter balloon was performed in 61%. By QCA, baseline lesion
length, reference diameter and % diameter stenosis were 17.27 
8.60mm, 2.85  0.42mm, and 57.1  9.8mm, respectively. All pa-
tients but 2 underwent angiographic re-evaluation at 6 months
follow-up (QCA analysis ongoing).
CONCLUSIONS The MMSES is novel bioresorbable scaffold technol-
ogy designed to provide optimal radial strength and temporary scaf-
fold within the coronary vessel, while maintaining efﬁcacy in
inhibiting neointimal hyperplasia, as well as to address a few limita-
tions of current fully bioabsorbable systems. The complete angio-
graphic results at post procedure and 6-month angiographic follow-up
comparing the MMSES versus the active control BVS will be presented
at the meeting.
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